Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities

International Journal of Technology Assessment in Health Care

Volumn 27, Issue 3, 2011, Pages 253-260

  Henshall, Chris ^a,b,e   Mardhani Bayne, Logan ^b   Frønsdal, Katrine B ^c   Klemp, Marianne ^c,d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Health Technology Assessment International   (Canada)

^c Norwegian Knowledge Center for the Health Services (NOKC)   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

Biomedical treatment outcome; Health; Insurance; Reimbursement; Technology assessment

Indexed keywords

BIOMEDICAL TREATMENT; DATA REQUIREMENTS; HEALTH TECHNOLOGY ASSESSMENTS; INFORMATION REQUIREMENT; NEW PRODUCT; PATIENT ACCESS; REGULATORY PROCESS; REIMBURSEMENT; TECHNOLOGY ASSESSMENT;

PRODUCT DEVELOPMENT; RATING;

HEALTH;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; HEALTH CARE INDUSTRY; HEALTH CARE POLICY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; INTERPERSONAL COMMUNICATION;

DEVICE APPROVAL; GOALS; GOVERNMENT REGULATION; INSURANCE COVERAGE; POLICY MAKING; PROBLEM SOLVING; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 80155212434     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462311000262     Document Type: Article

References (15)

1. Breckenridge A, Woods K, Walley T. Medicines regulation and health technology assessment. Clin Pharmacol Ther. 2010;87:152-154.
2. Chatham House. http://www.chathamhouse.org.uk (accessed March 2011).
3. Eichler H, Bloechl-Daum B, Abadie E, et al. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9:277-291.
4. European Medicines Agency (EMA). http://www.ema. europa.eu (accessed March 2011).
5. European Union Commission's Directives for Medical devices. http://ec.europa.eu/consumers/sectors/medical-devices (accessed March 2011).
6. European Union High Level Pharmaceutical Forum. High level pharmaceutical forum 2005-2008 final report. Core principles on relative effectiveness. http://ec.europa.eu/pharmaforum/docs/ev-20081002-frep-en.pdf (accessed March 2011).
7. Global Harmonization Task Force (GHFT). http://www.ghtf.org (accessed March 2011).
8. Health Technology Assessment International (HTAi). http://www.htai.org (accessed March 2011)
9. Health Technology Assessment International (HTAi) and the International Network of Agencies for Health Technology Assessment (INAHTA). HTA glossary. http://www.htaglossary.net (accessed March 2011).
10. Health Technology Assessment International (HTAi). Policy forum. http://www.htai.org/index.php?id=643 (accessed March 2011).
11. Hutton J, Trueman P, Facey K. Harmonisation of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511-517.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). http://www.ich.org (accessed March 2011).
13. International Network of Agencies for Health Technology Assessment (INAHTA). http://www.inahta.org (accessed March 2011).
14. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). http://www.ispor.org (accessed March 2011).
15. Progressive Licensing Project, Health Canada. http://www.hcsc.gc.ca/dhp- mps/homologation-licensing/plfs-hpfd-eng.php (accessed March 2011).